- Home
- SYBX vs HUBC Comparison
SYBX vs HUBC Comparison
Compare SYBX & HUBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYBX
- HUBC
- Stock Information
- Founded
- SYBX N/A
- HUBC 2017
- Country
- SYBX United States
- HUBC Israel
- Employees
- SYBX N/A
- HUBC N/A
- Industry
- SYBX Biotechnology: Pharmaceutical Preparations
- HUBC
- Sector
- SYBX Health Care
- HUBC
- Exchange
- SYBX Nasdaq
- HUBC Nasdaq
- Market Cap
- SYBX 16.5M
- HUBC N/A
- IPO Year
- SYBX N/A
- HUBC N/A
- Fundamental
- Price
- SYBX $1.20
- HUBC $3.62
- Analyst Decision
- SYBX
- HUBC
- Analyst Count
- SYBX 0
- HUBC 0
- Target Price
- SYBX N/A
- HUBC N/A
- AVG Volume (30 Days)
- SYBX 6.3K
- HUBC 155.1K
- Earning Date
- SYBX 03-06-2025
- HUBC 12-13-2024
- Dividend Yield
- SYBX N/A
- HUBC N/A
- EPS Growth
- SYBX N/A
- HUBC N/A
- EPS
- SYBX N/A
- HUBC N/A
- Revenue
- SYBX $8,000.00
- HUBC $33,357,000.00
- Revenue This Year
- SYBX N/A
- HUBC N/A
- Revenue Next Year
- SYBX N/A
- HUBC N/A
- P/E Ratio
- SYBX N/A
- HUBC N/A
- Revenue Growth
- SYBX N/A
- HUBC N/A
- 52 Week Low
- SYBX $1.15
- HUBC $2.65
- 52 Week High
- SYBX $1.96
- HUBC $21.70
- Technical
- Relative Strength Index (RSI)
- SYBX 34.47
- HUBC 37.97
- Support Level
- SYBX $1.27
- HUBC $2.65
- Resistance Level
- SYBX $1.32
- HUBC $6.30
- Average True Range (ATR)
- SYBX 0.05
- HUBC 0.74
- MACD
- SYBX -0.01
- HUBC -0.12
- Stochastic Oscillator
- SYBX 17.81
- HUBC 26.54
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.